Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06549634 · ClinicalTrials.gov registry record
Biomarkers of AKI in Patients Receiving Daratumumab
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 20
- Enrollment target
NCT06549634: Completed study, sponsored by Brigham and Women's Hospital.
NCT06549634 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06549634 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The goal of this prospective observational study is to understand changes in urinary and blood biomarkers associated with acute kidney injury (AKI) in patients newly diagnosed with multiple myeloma and being treated with Daratumumab SC. The aims of the study are: To measure changes in plasma and urinary biomarkers of AKI before initiation of Daratumumab therapy and 30 days after initiation of therapy. To establish whether these biomarkers serve to aid in early detection and prevention of AKI Participants will give urine and blood samples at their normally scheduled lab appointments.
Primary Outcome
The primary outcome(s) will be changes in plasma suPAR and urinary levels of DKK3 between treatment initiation of daratumumab (day 0, or up to 7 days prior) and day +30 (+/-7 days) from the time of treatment initiation.
Interventions
- DRUG Daratumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-01 |
| Est. Completion | 2026-01-15 |
What the finished NCT06549634 record still lists
NCT06549634 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Daratumumab is the first listed.
NCT06549634 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06549634 about?
NCT06549634 is a clinical study titled "Biomarkers of AKI in Patients Receiving Daratumumab". The goal of this prospective observational study is to understand changes in urinary and blood biomarkers associated with acute kidney injury (AKI) in patients newly diagnosed with multiple myeloma and being treated with Daratumumab SC. The aims of the study are: To measure changes in plasma and ur...
What is the current status of trial NCT06549634?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2024-09-01. Estimated completion is 2026-01-15.
What interventions are being tested in trial NCT06549634?
The interventions under investigation include: Daratumumab (DRUG).
Who is sponsoring clinical trial NCT06549634?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI